[go: up one dir, main page]

MX2019008489A - Tratamiento que comprende la administracion oral o gastrica de edaravona. - Google Patents

Tratamiento que comprende la administracion oral o gastrica de edaravona.

Info

Publication number
MX2019008489A
MX2019008489A MX2019008489A MX2019008489A MX2019008489A MX 2019008489 A MX2019008489 A MX 2019008489A MX 2019008489 A MX2019008489 A MX 2019008489A MX 2019008489 A MX2019008489 A MX 2019008489A MX 2019008489 A MX2019008489 A MX 2019008489A
Authority
MX
Mexico
Prior art keywords
edaravone
treatment
oral
gastric administration
pharmaceutical composition
Prior art date
Application number
MX2019008489A
Other languages
English (en)
Other versions
MX392901B (es
Inventor
Hyke Moolenaar Sytske
Van Der Geest Ronald
Original Assignee
Treeway Tw001 B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62908293&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2019008489(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/EP2017/067005 external-priority patent/WO2018133957A1/en
Application filed by Treeway Tw001 B V filed Critical Treeway Tw001 B V
Publication of MX2019008489A publication Critical patent/MX2019008489A/es
Publication of MX392901B publication Critical patent/MX392901B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La invención se refiere a una composición farmacéutica líquida para su uso en tratamiento médico, siendo dicha composición farmacéutica líquida una solución acuosa monofásica de 3-metil-1-fenil-2-pirazolin-5-ona no complejada (edavarona) y que comprende al menos un 75 % en peso de agua y 0,2-9 mg/ml de edaravona, en la que el tratamiento comprende la administración oral o gástrica de 10-250 ml de la composición farmacéutica líquida para proporcionar 30-300 mg de edaravona.
MX2019008489A 2017-01-17 2018-01-17 Tratamiento que comprende la administracion oral o gastrica de edaravona MX392901B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP17151741 2017-01-17
EP17180087 2017-07-06
PCT/EP2017/067005 WO2018133957A1 (en) 2017-01-17 2017-07-06 Medical treatment comprising enteral administration of edaravone
PCT/EP2018/051097 WO2018134243A1 (en) 2017-01-17 2018-01-17 Treatment comprising oral or gastric administration of edaravone

Publications (2)

Publication Number Publication Date
MX2019008489A true MX2019008489A (es) 2019-11-11
MX392901B MX392901B (es) 2025-03-24

Family

ID=62908293

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019008489A MX392901B (es) 2017-01-17 2018-01-17 Tratamiento que comprende la administracion oral o gastrica de edaravona

Country Status (14)

Country Link
US (1) US20190328712A1 (es)
EP (2) EP3785703A1 (es)
JP (2) JP7107624B2 (es)
KR (1) KR102550376B1 (es)
AU (1) AU2018209155B2 (es)
BR (1) BR112019014705A2 (es)
CA (1) CA3050037A1 (es)
DK (1) DK3551181T3 (es)
ES (1) ES2850873T3 (es)
IL (1) IL268127B2 (es)
MX (1) MX392901B (es)
PL (1) PL3551181T3 (es)
RU (1) RU2761967C2 (es)
WO (1) WO2018134243A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018133957A1 (en) 2017-01-17 2018-07-26 Treeway Tw001 B.V. Medical treatment comprising enteral administration of edaravone
ES2850873T3 (es) * 2017-01-17 2021-09-01 Treeway Tw001 B V Tratamiento que comprende la administración oral o gástrica de edaravona
BR112020000173A2 (pt) 2017-07-06 2020-07-07 Treeway Tw001 B.V. uso de edaravona no tratamento oral de distúrbios neurodegenerativos mediados por estresse oxidativo
MX2021005144A (es) 2018-11-02 2021-07-15 Mitsubishi Tanabe Pharma Corp Suspension de edaravona para administracion oral.
US11826352B2 (en) 2018-11-02 2023-11-28 Mitsubishi Tanabe Pharma Corporation Edaravone suspension for oral administration
KR20230098267A (ko) * 2020-11-12 2023-07-03 미쓰비시 타나베 파마 코퍼레이션 에다라본 경구 투여용 의약 조성물 및 그의 투여 방법
US12194025B2 (en) 2020-11-12 2025-01-14 Mitsubishi Tanabe Pharma Corporation Pharmaceutical composition for oral administration of edaravone and method of administering same
WO2024172852A1 (en) * 2023-02-16 2024-08-22 Slayback Pharma Llc Stable pharmaceutical compositions of edaravone

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3758164B2 (ja) 2000-10-24 2006-03-22 三菱ウェルファーマ株式会社 筋萎縮性側索硬化症（ａｌｓ）治療剤
JP2004002400A (ja) * 2002-04-23 2004-01-08 Mitsubishi Pharma Corp 軽微低体温療法を行うために用いる脳保護及び／又は脳機能正常化のための医薬
JP2004091441A (ja) * 2002-09-04 2004-03-25 Mitsubishi Pharma Corp ピラゾロン誘導体を含有する経口投与製剤
PL1714960T3 (pl) * 2004-02-09 2018-08-31 Mitsubishi Tanabe Pharma Corporation Nowy środek terapeutyczny przeciwko stwardnieniu zanikowemu bocznemu (ALS) lub chorobie którą można przypisać ALS
JP2008280253A (ja) * 2007-05-08 2008-11-20 Ohara Yakuhin Kogyo Kk エダラボン注射液
AU2008326593B2 (en) * 2007-11-21 2013-09-05 Techno Guard Co. Ltd. Pyrazolone derivative emulsion formulations
JP2009143902A (ja) * 2007-11-21 2009-07-02 Kowa Co エダラボンを含有する安定な水溶性製剤
JP2009143922A (ja) 2007-11-22 2009-07-02 Fujiyakuhin Co Ltd 注射剤
JP2009155315A (ja) 2007-12-26 2009-07-16 Fujiyakuhin Co Ltd 注射剤
JP2009280561A (ja) 2008-05-26 2009-12-03 Fujiyakuhin Co Ltd 注射剤
JP2010047482A (ja) * 2008-08-19 2010-03-04 Ohara Yakuhin Kogyo Kk エダラボン注射液
JP2010077104A (ja) 2008-08-29 2010-04-08 Nihon Pharmaceutical Co Ltd ３−メチル−１−フェニル−２−ピラゾリン−５−オン注射用水溶液
CN102159229A (zh) * 2008-11-20 2011-08-17 帝国制药美国公司 吡唑啉酮衍生物制剂
CN101953832B (zh) 2010-08-10 2012-02-15 南京师范大学 β-环糊精包合依达拉奉的口服药物组合物及其制备方法
CN102349893A (zh) * 2011-08-19 2012-02-15 福建天泉药业股份有限公司 依达拉奉药物组合物
ES2736007T3 (es) 2011-09-05 2019-12-23 Mitsubishi Tanabe Pharma Corp Agente medicinal para el tratamiento de la esclerosis lateral amiotrófica o la prevención de la progresión de una fase de la esclerosis lateral amiotrófica
CN113768879A (zh) 2016-03-16 2021-12-10 苏州澳宗生物科技有限公司 依达拉奉剂型
ES2850873T3 (es) * 2017-01-17 2021-09-01 Treeway Tw001 B V Tratamiento que comprende la administración oral o gástrica de edaravona

Also Published As

Publication number Publication date
RU2019125848A (ru) 2021-02-19
JP7415236B2 (ja) 2024-01-17
RU2761967C2 (ru) 2021-12-14
DK3551181T3 (da) 2020-11-30
JP2022137179A (ja) 2022-09-21
JP7107624B2 (ja) 2022-07-27
JP2020506959A (ja) 2020-03-05
EP3785703A1 (en) 2021-03-03
KR102550376B1 (ko) 2023-07-04
BR112019014705A2 (pt) 2020-02-18
US20190328712A1 (en) 2019-10-31
KR20190111929A (ko) 2019-10-02
EP3551181A1 (en) 2019-10-16
IL268127A (en) 2019-09-26
MX392901B (es) 2025-03-24
AU2018209155B2 (en) 2023-11-30
AU2018209155A1 (en) 2019-08-01
IL268127B1 (en) 2024-08-01
ES2850873T3 (es) 2021-09-01
IL268127B2 (en) 2024-12-01
RU2019125848A3 (es) 2021-04-12
CA3050037A1 (en) 2018-07-26
PL3551181T3 (pl) 2021-05-31
WO2018134243A1 (en) 2018-07-26
EP3551181B1 (en) 2020-11-18

Similar Documents

Publication Publication Date Title
MX2019008489A (es) Tratamiento que comprende la administracion oral o gastrica de edaravona.
MX2021004431A (es) Procesos novedosos.
MX2020011196A (es) Una sal sodica de n-((1,2,3,5,6,7-hexahidro-s-indacen-4-il)carbamo il)-1-isopropil-1h-pirazol-3-sulfonamida.
NZ780890A (en) Pharmaceutical compositions comprising meloxicam
MX2021004110A (es) Composiciones farmaceuticas que comprenden n-(3,5- dimetoxifenil)-n'-(1-metiletil)-n-[3-(1-metil-1h- pirazol-4-il)quinoxalin-6-il]etano-1,2-diamina.
PH12019502577A1 (en) Substituted indoline derivatives as dengue viral replication inhibitors
PH12019502095A1 (en) Substituted indoline derivatives as dengue viral replication inhibitors
MY196072A (en) Liquid Inhalation Formulation Comprising RPL554
PH12019502559A1 (en) Substituted indoline derivatives as dengue viral replication inhibitors
MX2020006459A (es) Compuestos de anillos fusionados 6,5 diaril sustituidos como inhibidores de c5ar.
PH12020551118A1 (en) Modified lipidated relaxin b chain peptides and their therapeutic use
PH12016500296A1 (en) Sodium channel modulators for the treatment of pain and diabetes
ECSP16084317A (es) Formulaciones farmacéuticas, procesos para la preparación y métodos de uso
TN2017000011A1 (en) Aqueous formulation comprising paracetamol and ibuprofen.
TN2019000032A1 (en) Pharmaceutical compositions and uses directed to lysosomal storage disorders
MX390101B (es) Tratamiento medico que comprende administracion enteral de edaravona
MX2017015202A (es) Formulaciones liquidas de celecoxib para administracion oral.
PH12020550775A1 (en) Pentosan polysulfate and medicine containing pentosan polysulfate
MX2019013665A (es) Tratamiento contra el cancer resistente a platino.
MX2021001349A (es) Un nuevo tratamiento medico para la inflamacion patologica.
EP3843785A4 (en) Compositions with synergistic permeation enhancers for drug delivery
PH12022550432A1 (en) Aqueous pharmaceutical composition of anti-pd1 antibody prolgolimab and use thereof
UA117544C2 (uk) Назальна композиція із вмістом морської води як ексципієнтом, що покращує стабільність
MX2021007324A (es) Terapia oral con acido 6,8-bis-benciltio-octanoico.
NZ760052A (en) Methods of treatment for cystic fibrosis